IHE is an exchange-traded fund — it holds a basket of underlying assets rather than being a single operating company.
Company fundamentals like P/E, revenue, EPS and profit margins don't apply to a fund — its value comes from the assets it holds, not its own earnings. Use the price chart, options and model forecast below for fund-level analysis.
An institutional-grade, numbers-driven thesis on IHE — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 18, 2026, TradersQuant's model rates iShares U.S. Pharmaceuticals ETF (IHE) 55/100 with a 12-month base-case forecast of $129.64 — +23.1% versus the current price of $105.31. iShares U.S. Pharmaceuticals ETF trades at $105.31 in the Financial Services sector, with a market capitalisation of $1.19B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for IHE is $129.64, implying +23.1% versus the current price. The model's 12-month scenario range runs from $122.51 (bear) to $141.46 (bull), with a base case of $129.64.
IHE currently carries a TradersQuant composite score of 55/100, which we read as a neutral-to-watch signal. Our 12-month price target of $129.64 implies +23.1% from $105.31. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for IHE is $129.64, about +23.1% versus the latest price of $105.31.
TradersQuant's 12-month model forecast for IHE is a base case of $129.64, ranging from $122.51 (bear) to $141.46 (bull), an expected return of +23.1%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for IHE over the next 12 months is $129.64 in the base case (bear $122.51, bull $141.46), versus today's price of $105.31. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for IHE — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates IHE's fair value at $134.18, implying +27.4% of expected upside versus the current price.
iShares U.S. Pharmaceuticals ETF does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
